NEW YORK, September 14 SPO Medical Inc. (SPOM)(http://finance.yahoo.com/q?s=SPOM.OB), a leading developer of biosensor andmicroprocessor technologies for use in portable monitoring devices, todayannounced it has been granted four additional patents by the United StatesPatent and Trademark Office, bringing the Company's intellectual property(IP) portfolio to a total of eight patents. These latest patents, developedby the SPO Medical engineering team, increases the Company's technologicalcompetitive edge in providing innovative, high performance oximetry solutionsfor a variety of market applications.
The four new patents primarily focus on several commercial applicationsrelating to the implementation of reflectance pulse oximetry for both medicaland non-medical markets. Use of pulse oximetry in these markets enablesaccurate and effective measurements of vital sign information in anon-invasive, convenient manner with the added ability for placement ofoptical sensors on various places on the body for maximum user comfort andconvenience. Furthermore, SPO has addressed the challenge of vital signmeasurements during motion, which until now had restricted the effective useof optical sensors for professional and homecare applications. Thisachievement should further assist SPO in the implementation of its technologyin a variety of commercial product configurations.
Michael Braunold, President and Chief Executive Officer of SPO Medicalcommented: "Building and maintaining a strong patent portfolio continues tobe one of the strategic goals for the Company, enabling us to bring effectivepulse oximetry solutions to the vital sign measurement market for bothmedical professional and non-medical consumer product applications. We haveachieved these goals as a result of several years of research together withmarket experience gained from our commercial medical product line. We haveseveral additional new patents pending which can further enhance our IPportfolio and asset value going forward."
SPO recently announced a breakthrough in the use of its core patents formeasurement of the heart rate using a conventional sports wrist watch,negating the need of the traditional chest strap currently used by mostsports and leisure watch manufacturers. This solution encompasses the SPOcore technology in addition to resolving measurement under motion conditions.Braunold continued; "Commercially, we believe that our expanded IP portfolioasset can attract interest from both medical and non-medical corporations whoare seeking commercial solutions based on our innovative technology, furthercontributing to potentially increasing value for the SPO Medicalshareholders."
About SPO Medical:
SPO Medical (SPOM) (http://finance.yahoo.com/q?s=SPOM.OB) a leadingdeveloper of biosensor and microprocessor technologies for use in portablemonitoring devices to capture life-saving and life-enhancing informationwithin four key markets: medical care; home and remote-care; sports andwellness; and safety and security. Its patented technology uses informationgathered from the reflectance of light on the human blood stream, in anon-invasive manner, to monitor key vital signs. The Company distributes itsproducts through a network of distributors and also licenses its technologiesto appropriate client corporations for commercialization and distribution.For more information, visit http://www.spomedical.com andhttp://www.spobaby.com.
Forward Looking Statements:
This press release contains forward-looking statements that involvesubstantial uncertainties and risks. These forward-looking statements arebased upon our current expectations, estimates and projections about ourbusiness and our industry, and that reflect our beliefs and assumptions basedupon information available to us at the date of this release. We cautionreaders that forward-looking statements are predictions based on our currentexpectations about future events. These forward-looking statements are notguarantees of future performance and are subject to risks, uncertainties andassumptions that are difficult to predict. Our actual results, performance orachievements could differ materially from those expressed or implied by theforward-looking statements as a result of a number of factors, including butnot limited to, patent protection for our products and technologies, marketacceptance of our products and new product applications, product performance,size of prospective markets, revenues assessments, changes in economicconditions generally and the medical devices market specifically, changes intechnology, legislative or regulatory changes that affect us, the sufficiencyand availability of working capital, the introduction of competing products,changes in our operating strategy or development plans and the risks anduncertainties discussed under the heading "Risk Factors" in Item 1 of ourAnnual Report on Form 10-K for the fiscal year ended December 31, 2008. Weundertake no obligation to revise or update any forward-looking statement forany reason.
SPO Medical Contact:
Jeff Feuer, Chief Financial Officer. Tel: +1-866-991-SPOM (7766) oremail: [email protected]
SOURCE SPO Medical Inc